Osteoporosis drug strontium ranelate returns to the UK
The osteoporosis medication strontium ranelate, is once again available again for people with osteoporosis in the UK, the National Osteoporosis Society reports.
The drug was previously called Protelos but was pulled from the UK market in August 2017 following safety concerns about the it being connected to cardiovascular risks, which had led to its limited use and a continuous decline in the number of people being treated with it.
Now Aristo has now taken on the manufacturing of strontium ranelate, which is available for prescription for the treatment of severe osteoporosis in postmenopausal women and adult men who are at high risk of fracture.
“I’m pleased that strontium ranelate is available as a drug treatment again,” said Dr Nicola Peel, clinical adviser for the National Osteoporosis Society. “While it is not a suitable drug treatment for everyone with osteoporosis because of some of the potential side-effects, it may be the right choice for some patients – many of whom would otherwise have no other suitable treatment to reduce their risk of broken bones.”
To contact the National Osteoporosis Society click here.
Arthritis Digest Magazine was selected by Feedspot as one of the Top 5 Arthritis Blogs on the internet in 2018.
For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.